Cramer turned bearish when he heard the primary end point of their alzheimers drug (Solanezumab), changed from affecting a person’s daily ability to function, to cognition. His knee-jerk reaction was to "sell, sell, sell". Clown. The cognition endpoint alone would has the potential to be a massive success. Additionally, other late stage drug remains promising for the overall portfolio of drugs. Meanwhile, the company continues to generate significant profits every quarter
The end of 2016 will be important regarding to FDA filings. We're currently well below analyst targets ~$90. I believe $90 is attainable within the next 12 months. This gives 18% up-side from our current level of $76.33. Add dividends and the return is slightly higher.
Also, LLY isn't the target of politicians regarding drug pricing. Yes, even their drugs are expensive, but fair. Margins are justified.
I think I remember him liking LLY anywhere under $80 so he gets out, I guess, well under there, and now it's back up close to $80 again....I do like to rub it in a bit on 'fast money' types, I admit.
Price action in LLY since the time Cramer recommended LLY, to the time he dumped it from his charity fund, to the current price, clearly indicates that he has been persistently on the wrong side of the trade or even longer term investment.
You blowhard, hot air BSer..
What makes you think LLY will go down? Surely a person that bought 100,000 shares with a current value of more than $7.6M, had good reason to initiate the position. You must have an equally good reason for closing the position. What's the reason?
I bought some of them today
This company had better wake up and smell the coffee soon. We could see 80-90% fall off rates for Viagra if the claims being made by CANF are even remotely true. (I don't want to take that chance, do you?)